Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated)

E. Wesley Ely, Pierre‐François Laterre, Derek C. Angus, Jeffrey D. Helterbrand, Howard Levy, Jean-François Dhainaut, Jean Louis Vincent, William L. Macias, Gordon R. Bernard

Article2003

Baseline Characteristics and Survival of Adult Severe Sepsis Patients Treated With Drotrecogin Alfa (Activated) in a Global, Single-Arm, Open-Label Trial (ENHANCE

Arthur P. Wheeler, Christopher Doig, Theressa J. Wright, Kar Wong, Jean Louis Vincent, Gordon R. Bernard

Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated)

Abstract

Discussion(0)

Related publications

Effects of drotrecogin alfa activated on microcirculatory alterations in patients with severe sepsis

Drotrecogin alfa (activated) in the treatment of severe sepsis

Drotrecogin Alfa (Activated) in the Treatment of Severe Sepsis

Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis

Baseline Characteristics and Survival of Adult Severe Sepsis Patients Treated With Drotrecogin Alfa (Activated) in a Global, Single-Arm, Open-Label Trial (ENHANCE